# AFYX Therapeutics A/S

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/afyx-therapeutics-a-s

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.afyxtx.com
- Total disclosed funding: $18M
- Latest round: Series A (May 9, 2017)
- Investors on record: 3

## About

AFYX Therapeutics A/S specializes in the development of innovative pharmaceutical products aimed at addressing unmet medical needs, particularly in labor induction and specific patient care therapies.Founded in 2013, AFYX Therapeutics A/S is based in Copenhagen, Denmark, and focuses on the development of pharmaceutical solutions. The company has completed three deals, with the most recent funding round being a VENTURE DEBT round amounting to USD 13.00 mn led by Sofinnova Investments. In January 2024, Inphena acquired AFYX Therapeutics from its previous investors including Lundbeckfond Ventures and Novo Seeds for an undisclosed amount. The company is led by CEO Nishan De Silva.AFYX Therapeutics specializes in developing innovative pharmaceutical products that focus on addressing unmet medical needs through a process termed 'Reversed Innovation.' The company’s core offerings include Gefena, a Misoprostol 25µg tablet designed for the induction of labor, and Diaphine, which serves a specific therapeutic purpose in patient care. These products leverage existing technologies to tackle new medical challenges, making them relevant in various healthcare settings. AFYX aims to serve healthcare providers and patients in Denmark, Norway, and other regions in Europe where there is a demand for enhanced medical solutions.In Q4 2024, AFYX Therapeutics reported total revenue of DKK 12.9 million, a substantial increase from DKK 8.9 million in the same period the previous year. This growth can be attributed to increased sales of flagship products such as Diaphine and Nimorazole, with notable demand from clients in Norway. The company operates through a B2B transaction model, engaging with healthcare providers, hospitals, and pharmacies that require these pharmaceutical products.AFYX Therapeutics plans to broaden its product offerings with new pharmaceuticals aimed at enhancing patient care, although specific upcoming products and release dates were not detailed. The company targets expansion into additional European markets to enhance its reach by 2025. The recent funding of USD 13.00 mn will support these initiatives, facilitating research and development as well as market entry efforts. Additionally, following the acquisition by Inphena in January 2024, AFYX will leverage new resources to accelerate its growth strategy.

## Funding rounds

- Series A, May 9, 2017, $18M — Sofinnova Investments, Lundbeckfond Ventures, Novo Seeds

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A
- Novo Seeds — Series A